HUP0300392A2 - Benzo[a]phenazin-11-carboxamide derivatives, their use for producing pharmaceutical compositions with effect joint inhibitors of topomerase i and ii, process for their preparation and their intermediates - Google Patents
Benzo[a]phenazin-11-carboxamide derivatives, their use for producing pharmaceutical compositions with effect joint inhibitors of topomerase i and ii, process for their preparation and their intermediatesInfo
- Publication number
- HUP0300392A2 HUP0300392A2 HU0300392A HUP0300392A HUP0300392A2 HU P0300392 A2 HUP0300392 A2 HU P0300392A2 HU 0300392 A HU0300392 A HU 0300392A HU P0300392 A HUP0300392 A HU P0300392A HU P0300392 A2 HUP0300392 A2 HU P0300392A2
- Authority
- HU
- Hungary
- Prior art keywords
- topomerase
- phenazin
- benzo
- intermediates
- preparation
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- QDGSQQMUZONPER-UHFFFAOYSA-N benzo[a]phenazine-11-carboxamide Chemical class C1=CC=CC2=C(N=C3C(C(=O)N)=CC=CC3=N3)C3=CC=C21 QDGSQQMUZONPER-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000000543 intermediate Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 102000003915 DNA Topoisomerases Human genes 0.000 abstract 1
- 108090000323 DNA Topoisomerases Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 abstract 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- -1 hydroxy- Chemical class 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000005156 substituted alkylene group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/46—Phenazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
A találmány tárgyát a topoizomeráz I és/vagy topoizomeráz II inhibitorhatású, daganatos betegségek kezelésére használható általános képletűvegyületek - ahol előnyösen R1, R2, R3 és R4 az aromás gyűrűk szokásosszubsztituensei közül választhatók, de előnyösen R1-R3 hidrogénatom;és R4 alkoxi-, hidroxi-, hidroxi-alkil- vagy cianocsoport vagyhalogénatom; R5, R6 és R7 egymástól függetlenül hidrogén- vagyhalogénatom, hidroxi-, alkoxi- vagy alkil-tio-csoport; Q adott esetbenszubsztituált alkiléncsoport; és R8 és R9 hidrogénatom vagyalkilcsoport; vagy R8 és R9 együttesen adott esetben egy továbbihéteroatomot tartalmazó gyűrűt képez; vagy R8 és R9 egyike adottesetben közbeékelt heteroatomo(ka)t tartalmazó alkiléncsopoxt, amely aQ alkiléncsoport valamely szénatomjához kapcsolódva gyűrűt képez - éssóik, előállításukra szolgáló eljárás, ezeket tartalmazógyógyszerkészítmények és alkalmazásuk képezik. ÓThe subject of the invention is topoisomerase I and/or topoisomerase II inhibitory compounds of the general formula which can be used for the treatment of cancer diseases - where preferably R1, R2, R3 and R4 can be chosen from the usual substituents of aromatic rings, but preferably R1-R3 is a hydrogen atom; and R4 is alkoxy-, hydroxy- , a hydroxyalkyl or cyano group or a halogen atom; R 5 , R 6 and R 7 are independently a hydrogen or halogen atom, a hydroxy, alkoxy or alkylthio group; Q is an optionally substituted alkylene group; and R8 and R9 are hydrogen or alkyl; or R8 and R9 together optionally form a ring containing an additional heteroatom; or one of R8 and R9 is optionally an alkylene group containing an intervening heteroatom(s), which forms a ring when connected to a carbon atom of the alkylene group aQ - and their salts, the process for their production, pharmaceutical preparations containing them and their use. HE
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9928542.1A GB9928542D0 (en) | 1999-12-02 | 1999-12-02 | Pharmaceutical compounds |
| PCT/GB2000/004609 WO2001046157A1 (en) | 1999-12-02 | 2000-12-01 | Benzo[a]phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase i and ii |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0300392A2 true HUP0300392A2 (en) | 2003-07-28 |
| HUP0300392A3 HUP0300392A3 (en) | 2003-09-29 |
Family
ID=10865607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0300392A HUP0300392A3 (en) | 1999-12-02 | 2000-12-01 | Benzo[a]phenazin-11-carboxamide derivatives, their use for producing pharmaceutical compositions with effect joint inhibitors of topomerase i and ii, process for their preparation and their intermediates |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1240148A1 (en) |
| JP (1) | JP2003518103A (en) |
| KR (1) | KR100767613B1 (en) |
| CN (1) | CN1304380C (en) |
| AU (1) | AU784397B2 (en) |
| BR (1) | BR0016093A (en) |
| CA (1) | CA2392873A1 (en) |
| GB (2) | GB9928542D0 (en) |
| HK (1) | HK1046133B (en) |
| HU (1) | HUP0300392A3 (en) |
| MX (1) | MXPA02005476A (en) |
| MY (1) | MY136029A (en) |
| PL (1) | PL356482A1 (en) |
| TW (1) | TWI280242B (en) |
| WO (1) | WO2001046157A1 (en) |
| ZA (1) | ZA200204296B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2433071A (en) * | 2005-12-05 | 2007-06-13 | Kontrakt Technology Ltd | Organic acids comprising planar conjugated heterocyclic molecular system, & photoelectric layer thereof with rodlike supramolecules for use in solar cell |
| CN102898388B (en) * | 2012-09-26 | 2014-12-03 | 浙江工业大学 | Method for synthesizing substituted benzo[alpha]phenazine compound |
| CN103360329B (en) * | 2013-07-18 | 2015-11-18 | 中国科学院南海海洋研究所 | One class compound phenazine and preparing the application in antitumor drug |
| CN106554321B (en) * | 2015-09-25 | 2019-05-28 | 陆源 | A kind of azophenlyene substance, preparation method and its application |
| CN113461623A (en) * | 2021-07-14 | 2021-10-01 | 长江大学 | Antiviral compound and preparation method and application thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE195869T1 (en) * | 1992-05-28 | 2000-09-15 | Xenova Ltd | ACRIDINE CARBOXAMIDE FOR THE TREATMENT OF CANCER |
| US5696131A (en) * | 1993-01-22 | 1997-12-09 | Xenova Limited | Treatment of cancers |
| IL129096A0 (en) * | 1996-09-23 | 2000-02-17 | Univ Rutgers | Substituted heterocycles as anti-tumor agents |
| WO1998045272A1 (en) * | 1997-04-07 | 1998-10-15 | Latrobe University | Topoisomerase inhibitors |
-
1999
- 1999-12-02 GB GBGB9928542.1A patent/GB9928542D0/en not_active Ceased
-
2000
- 2000-12-01 CN CNB008187096A patent/CN1304380C/en not_active Expired - Fee Related
- 2000-12-01 CA CA002392873A patent/CA2392873A1/en not_active Abandoned
- 2000-12-01 MX MXPA02005476A patent/MXPA02005476A/en not_active Application Discontinuation
- 2000-12-01 JP JP2001547068A patent/JP2003518103A/en active Pending
- 2000-12-01 AU AU17184/01A patent/AU784397B2/en not_active Ceased
- 2000-12-01 BR BR0016093-8A patent/BR0016093A/en not_active IP Right Cessation
- 2000-12-01 MY MYPI20005670A patent/MY136029A/en unknown
- 2000-12-01 PL PL00356482A patent/PL356482A1/en not_active Application Discontinuation
- 2000-12-01 KR KR1020027007033A patent/KR100767613B1/en not_active IP Right Cessation
- 2000-12-01 GB GB0215275A patent/GB2373499B/en not_active Expired - Fee Related
- 2000-12-01 WO PCT/GB2000/004609 patent/WO2001046157A1/en active Application Filing
- 2000-12-01 EP EP00979799A patent/EP1240148A1/en not_active Withdrawn
- 2000-12-01 HU HU0300392A patent/HUP0300392A3/en unknown
- 2000-12-02 TW TW089125715A patent/TWI280242B/en not_active IP Right Cessation
-
2002
- 2002-05-29 ZA ZA200204296A patent/ZA200204296B/en unknown
- 2002-10-10 HK HK02107392.7A patent/HK1046133B/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2392873A1 (en) | 2001-06-28 |
| GB2373499A (en) | 2002-09-25 |
| KR100767613B1 (en) | 2007-10-19 |
| AU1718401A (en) | 2001-07-03 |
| ZA200204296B (en) | 2003-05-29 |
| KR20020070305A (en) | 2002-09-05 |
| PL356482A1 (en) | 2004-06-28 |
| BR0016093A (en) | 2002-08-20 |
| GB0215275D0 (en) | 2002-08-14 |
| HUP0300392A3 (en) | 2003-09-29 |
| GB2373499B (en) | 2004-11-17 |
| EP1240148A1 (en) | 2002-09-18 |
| JP2003518103A (en) | 2003-06-03 |
| CN1304380C (en) | 2007-03-14 |
| GB9928542D0 (en) | 2000-02-02 |
| HK1046133B (en) | 2005-04-15 |
| CN1433406A (en) | 2003-07-30 |
| MY136029A (en) | 2008-07-31 |
| MXPA02005476A (en) | 2003-09-22 |
| WO2001046157A1 (en) | 2001-06-28 |
| AU784397B2 (en) | 2006-03-23 |
| HK1046133A1 (en) | 2002-12-27 |
| TWI280242B (en) | 2007-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP9900006A2 (en) | Cyclic gmp-specific phosphodiesterase inhibitors, their production and medicament containing them | |
| HUP9902471A2 (en) | Piperazine and piperidine compounds, process for their preparation and pharmaceutical compositions containing the same | |
| HUP0300565A2 (en) | 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors, their use, process for their preparation and pharmaceutical compositions containing them | |
| DK1533292T3 (en) | Dibenzylamine compound and its medical use | |
| HUP9701048A2 (en) | Novel process for preparing sildenafil and new intermediates utilized therein | |
| HUP0204245A2 (en) | Novel n-azabicyclo-amide derivatives, process for their preparation, pharmaceutical compositions containing them and their use | |
| HUP0100051A2 (en) | Antimicrobial quinolones, their compositions and uses | |
| HUP9900973A2 (en) | Carbamoyloxy derivatives of mutiline with antibacterial activity, pharmaceutical compns. contg. them and process for preparing the said compds. | |
| HUP0002347A2 (en) | Use of hydantoin, oxazole and pyrrole derivatives for the preparation of pharmaceutical compositions inflammatory disease treating | |
| HUP0303756A2 (en) | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands and process for their preparation and pharmaceutical compositions containing them | |
| HUP0302167A2 (en) | Quinoline derivatives as metabotropic glutamate receptor antagonists, pharmaceutical compositions containing them and process for producing them | |
| HUP0001446A2 (en) | 4,4-disubstituted-3,4-dihydro-2(1h)-quinazolinone derivatives as hiv reverse transcriptase inhibitors, their use and pharmaceutical compositions containing them | |
| HUP0001498A2 (en) | Farnesyl transferase inhibiting 1,8-annelated imidazolyl-quinolinone derivatives, their intermediates, pharmaceutical compositions thereof and process for their preparation | |
| HUP0401009A2 (en) | 1-aryl-or 1-alkylsulfonylbenzole derivatives as 5-hydroxytryptamine-6 ligands, process for their preparation and pharmaceutical compositions containing them | |
| HUP0301811A2 (en) | Compounds having hypolipedemic and hypocholesteremic activities, process for their prreparation and pharmaceutical compositions containing them and their use, intermediates | |
| ES8802610A1 (en) | 2-quinolinyl methoxy compounds, medical uses and intermediates therefor | |
| HUP0101688A2 (en) | Heterocyclically substituted amides and their use for producing pharmaceutical compositions | |
| HUP0300427A2 (en) | Hydroxyphenyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatement of pain, process for their preparation and pharmaceutical compositions containing them | |
| HUP0203422A2 (en) | Imidazole derivatives as phosphodiesterase vii inhibitors, process for their preparation and pharmaceutical compositions containing them | |
| HUP0300619A2 (en) | Pharmaceutical compositions containing oxadiazole derivatives having anticancer effects | |
| HUP9901387A2 (en) | Distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents | |
| HUP0000321A2 (en) | Aromatic amine derivatives having nos inhibitory effect, process for producing them and pharmaceutical compositions containing them | |
| HUP0300392A2 (en) | Benzo[a]phenazin-11-carboxamide derivatives, their use for producing pharmaceutical compositions with effect joint inhibitors of topomerase i and ii, process for their preparation and their intermediates | |
| HUP0300562A2 (en) | Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain, process for their preparation and pharmaceutical compositions containing them | |
| HUP9700708A2 (en) | N-(9-pyrimido1,2-aòindolyl)-methyl-phenylacetylò-phenylglycinol derivatives, pharmaceutical compositions containing them, process for producing them and intermediates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |